Clinical Trial Detail

NCT ID NCT02335411
Title A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059)
Recruitment Active, not recruiting
Gender
Phase Phase II
Variant Requirements Yes
Sponsors Merck Sharp & Dohme Corp.
Indications

gastroesophageal junction adenocarcinoma

gastric adenocarcinoma

Therapies

Cisplatin + Fluorouracil + Pembrolizumab

Pembrolizumab

Age Groups: senior adult

Additional content available in CKB BOOST